Budget Amount *help |
¥44,850,000 (Direct Cost: ¥34,500,000、Indirect Cost: ¥10,350,000)
Fiscal Year 2022: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
Fiscal Year 2021: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
Fiscal Year 2020: ¥12,090,000 (Direct Cost: ¥9,300,000、Indirect Cost: ¥2,790,000)
|
Outline of Final Research Achievements |
Replication-incompetent adenovirus (Ad) vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. In addition, oncolytic Ad are among the most promising oncolytic viruses. In this study, we have done several basic studies about the improvement of recombinant Ad. Following recombinant Ad were developed and evaluated. Oncolytic Ad fully composed of human Ad serotype 35, hexon/fiber-modified Ad vectors for circumventing neutralizing anti-Ad antibodies, and Ad vectors having gene editing functions.
|